ENYO Pharma strengthens its leadership team with a NASH expert and announces that its Phase 1b trial in chronic HBV infected patients is on track with its FXR agonist EYP001

Published on 27/02/2018

Lyon, February 27, 2018 – ENYO Pharma SA, a privately held biopharmaceutical company developing innovative new drug candidates by mimicking virus strategies to modulate host cellular functions, has today announced that it is strengthening its leadership team with the appointment of a VP Non-Clinical Development & Product Profiling. ENYO Pharma also confirms that its Phase Ib trial evaluating the safety of EYP001 in chronic HBV infected patients is progressing well in Europe and in the Asia-Pacific region and is set to deliver its results in Q2 2018.

Read next in 'Press releases'

• ENYO Pharma announces a €39 million Series C financing and FDA clearance to advance Vonafexor in a Phase 2 clinical trial for patients with Alport syndrome
• ENYO Pharma Announces Two Vonafexor Data Presentations at AASLD The Liver Meeting
• ENYO Pharma Announces 16 Weeks Vonafexor (EYP001) Top-Line Interim Results from Two on-going Phase 2a Studies in Chronic Hepatitis B Patients
• ENYO Pharma Announces Positive Vonafexor (EYP001) Results for the LIVIFY Phase 2a Study in F2-F3 NASH Patients over 12 weeks
• Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats